With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News

US FDA's Accelerated Approval for Drugs Needs More Transparency, Says Research Firm

The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical...

Common Genetic Cause of Intellectual Disability Identified

A newly identified recessive neurodevelopmental disorder may be among the most common genetic causes of intellectual disability and epilepsy, new research suggests.

Roche: New Elevidys Study After Feedback From EU Regulator

Roche said it is initiating a late stage study for its ⁠gene therapy Elevidys following feedback from the European drug regulator.

New Evidence Strengthens the Case for Iatrogenic Alzheimer’s

Researchers report the first autopsy-confirmed case of Alzheimer's disease following suspected medical transmission, but experts say definitive causation may remain elusive.

Experts Push Back on WHO’s ‘Misleading’ Portrayal of ECT

Leading psychiatry groups say WHO guidance on ECT risks stigmatizing and reducing access to a safe, effective, and sometimes life-saving treatment for patients with severe mental illness.

Do Early Birds Have a Lower Risk for ALS?

Earlier bedtime and wake time and regular physical activity are associated with a significant reduction in ALS risk, a new study shows.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical...

A newly identified recessive neurodevelopmental disorder may be among the most common genetic causes of intellectual disability and epilepsy, new research suggests.

Roche said it is initiating a late stage study for its ⁠gene therapy Elevidys following feedback from the European drug regulator.

Researchers report the first autopsy-confirmed case of Alzheimer's disease following suspected medical transmission, but experts say definitive causation may remain elusive.

Leading psychiatry groups say WHO guidance on ECT risks stigmatizing and reducing access to a safe, effective, and sometimes life-saving treatment for patients with severe mental illness.

Earlier bedtime and wake time and regular physical activity are associated with a significant reduction in ALS risk, a new study shows.

News All Time

Late Complications Common After CVT, Even After Recovery

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Activity Trackers May Predict MS Progression

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

WHO Warns Of Health Risks From 'Black Rain' in Iran

The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on ⁠oil facilities could cause respiratory problems.

Wildfire Smoke Tied to Higher Stroke Risk, Greater Severity

Short-term surges in air pollution from wildfire smoke have been linked to a greater incidence and severity of stroke.

Therapeutic Research in Alzheimer’s Disease: What Is New?

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Reframing Dyslexia: Ancient Genes, Modern Skill

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Adults With IDDs Face ‘Mental Health Crisis’

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

Recommended News For You

Since 2000, the outlook for multiple myeloma has improved.

A novel blood test may enable the early identification of common, fatal cancers.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Ketamine plus psychotherapy for "excellent" PTSD

Hereditary cancer has a rare and underreported cause.

Dissociative identity disorder: method or fact?

Recommended Articles For You

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

The Latest Research on Wiskott Aldrich Syndrome  

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program 

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

2.

According to new studies, some cancer patients can safely forego radiation therapy.

3.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

4.

Guidelines for cervical cancer screening and the risk of preterm birth in young women.

5.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

1.

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders

2.

Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance

3.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

4.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

5.

Unveiling the Mystery Behind Lymphovascular Invasion

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot